BioSpace News Archive

Quantabio , a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced a new optimized Bead Booster chemistry for its sparQ RNA-Seq HMR Kit, an ultra-fast RNA next-generation sequencing (NGS) library preparation tool with ribosomal RNA (rRNA) and globin mRNA depletion.

InvisiShield Technologies Ltd. today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479.

Oxford Nanopore Technologies plc and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, announce a collaboration to make available 4bases kits with Oxford Nanopore sequencing technology.

QSAM Biosciences, Inc. is pleased to announce that it has been invited to provide updates on its clinical trial evaluating CycloSam® for the treatment of metastatic bone cancer at the Emerging Growth Conference on Wednesday, March 22, 2023, at 2:50 PM EST.

SurgVision, a high-tech company developing pioneering solutions for fluorescence-guided surgical and interventional oncology, part of the Bracco Group, announces that it has received 510(k) clearance from the U.S. Food and Drug Administration for the EXPLORER AIR® II for use with Pafolacianine (CYTALUX, On Target Laboratories Inc.) during intraoperative fluorescence imaging.

India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future.

LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches and other wearable devices, with an anticipated 100 diseases and disorders within the next two years—revolutionizing healthcare and improving consumers’ lives.

Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it has received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for its molecular test to detect the mpox virus (formerly known as monkeypox).